DRB18

CAS No. 2863686-81-9

DRB18( —— )

Catalog No. M33802 CAS No. 2863686-81-9

DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 146 Get Quote
5MG 227 Get Quote
10MG 359 Get Quote
25MG 702 Get Quote
50MG 1132 Get Quote
100MG 1485 Get Quote
500MG 2961 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DRB18
  • Note
    Research use only, not for human use.
  • Brief Description
    DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.
  • Description
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity.
  • In Vitro
    Cell Proliferation Assay Cell Line:GLUT1-4-expressed HEK293 cell lines Concentration:0-10 μM Incubation Time:30 min Result:Reduced glucose uptake in these cell lines in a dose-dependent manner with IC50s varying from ~ 900 nM to ~ 9 μM.Cell Cycle AnalysisCell Line:A549 Concentration:5 and 10 μM Incubation Time:72 hours Result:Caused cell cycle arrest in the G1/S phase transition.Western Blot Analysis Cell Line:A549 Concentration: 5 and 10 μM Incubation Time:72 hours Result:Reduced expression of glycosylated GLUT1 and GLUT2-4 in A549 cells in a dose-dependent manner.Western Blot Analysis Cell Line:A549 Concentration:5 and 10 μM Incubation Time:72 hours Result:Reduced expression of glycosylated GLUT1 and GLUT2-4 in A549 cells in a dose-dependent manner.
  • In Vivo
    Animal Model:Male NU/J nude mice (3-4 weeks; tumor cell-injected) Dosage:10 mg/kg Administration:IP; thrice a week for 5 weeks Result:The tumors were 44% smaller by volume and 43% smaller by weight, also showed DRB18 decreased expression of GLUT1-4 (Fig. 5f) and reduced proliferative capacity within the xenografted tumor.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    transporter
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2863686-81-9
  • Formula Weight
    382.88
  • Molecular Formula
    C22H23ClN2O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (130.59 mM; Ultrasonic (<60°C)
  • SMILES
    CC1=C(C=C(C=C1)CNC2=C(C=C(C=C2)Cl)NCC3=CC(=C(C=C3)C)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9(1):14. Published 2021 Mar 26.?
molnova catalog
related products
  • 2-Methylbenzene-1-su...

    Used for saccharin, pharmaceutical intermediates, etc.

  • Isokaempferide

    Isokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion.

  • 16-anhydro-b-D-Gluco...

    16-anhydro-b-D-Glucose (Levoglucosan) is an anhydrohexose that is the 16-anhydro-derivative of beta-D-glucopyranose. It is formed from the pyrolysis of carbohydrates such as starch and cellulose. Levoglucosan can also be utilized in the synthesis of chiral polymers such as unhydrolysable glucose polymers.